Behrens Frank, Tony Hans-Peter, Koehm Michaela, Schwaneck Eva C, Gnann Holger, Greger Gerd, Burkhardt Harald, Schmalzing Marc
Division of Rheumatology, University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany.
Project Group Translational Medicine & Pharmacology TMP, Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Frankfurt am Main, Germany.
Clin Rheumatol. 2020 Sep;39(9):2583-2592. doi: 10.1007/s10067-020-05038-y. Epub 2020 Mar 23.
The goal of this study was to evaluate the long-term impact of adalimumab therapy on work-related outcomes in employed patients with rheumatoid arthritis (RA).
We utilized data from an observational cohort of German patients who initiated adalimumab treatment during routine clinical care. Analyses were based on employed patients (part-time or full-time) who continued adalimumab treatment for 24 months. Major outcomes were self-reported sick leave days in the previous 6 months, absenteeism, presenteeism, and total work productivity impairment as assessed by the Work Productivity and Activity Impairment (WPAI) questionnaire and disease activity assessments. The normal number of sick leave days was based on data from the German Federal Statistical Office.
Of 783 patients, 72.3% were women, mean age was 47.9 years, and mean disease duration was 7.8 years. At baseline (before adalimumab initiation), 42.9% of patients had higher than normal sick leave days (> 5) in the previous 6 months. During 24 months of adalimumab treatment, 61% of patients with higher than normal sick leave days at baseline returned to normal sick leave values (≤ 5 days/6 months). Overall, mean sick leave days/6 months decreased from 14.8 days at baseline to 7.4 days at month 24. Improvements were observed in WPAI assessments and disease activity measures, although presenteeism levels remained high (32.2% at month 24).
Adalimumab treatment was associated with strong and sustained improvements in work-related outcomes in employed patients who continued on adalimumab for 24 months. Presenteeism appears to be the work outcome most resistant to improvement during RA treatment.
NCT01076205 Key Points • Long-term adalimumab therapy was associated with sustained improvements in work outcomes in patients with rheumatoid arthritis. • Despite improvements in sick leave days and work absenteeism, presenteeism (impairment while at work) remained relatively high.
本研究的目的是评估阿达木单抗治疗对类风湿关节炎(RA)在职患者工作相关结局的长期影响。
我们利用了来自德国患者观察队列的数据,这些患者在常规临床护理期间开始接受阿达木单抗治疗。分析基于继续接受阿达木单抗治疗24个月的在职患者(兼职或全职)。主要结局包括过去6个月自我报告的病假天数、旷工、出勤主义以及通过工作效率和活动障碍(WPAI)问卷及疾病活动评估所评估的总体工作效率损害。正常病假天数基于德国联邦统计局的数据。
在783例患者中,72.3%为女性,平均年龄为47.9岁,平均病程为7.8年。在基线时(开始使用阿达木单抗之前),42.9%的患者在过去6个月的病假天数高于正常水平(>5天)。在阿达木单抗治疗的24个月期间,基线时病假天数高于正常水平的患者中有61%恢复到正常病假值(≤5天/6个月)。总体而言,平均病假天数/6个月从基线时的14.8天降至第24个月时的7.4天。在WPAI评估和疾病活动指标方面观察到改善,尽管出勤主义水平仍然较高(第24个月时为32.2%)。
阿达木单抗治疗与继续使用阿达木单抗24个月的在职患者的工作相关结局的显著且持续改善相关。出勤主义似乎是类风湿关节炎治疗期间最难以改善的工作结局。
NCT01076205要点 • 长期阿达木单抗治疗与类风湿关节炎患者的工作结局持续改善相关。 • 尽管病假天数和旷工有所改善,但出勤主义(工作时的损害)仍然相对较高。